Page 17 - Agvhd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the Journal of Clinical Oncology. A New Drug Application (NDA) for belumosudil is currently under Priority Review by the U.S Food and Drug Administration (FDA) for the treatment of patients with cGVHD, with a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2021. "The results from our first clinical study in cG...

MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) Topline data from the Phase 2 HERACLES clinical trial with MaaT013 will be announced near-term MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic, MaaT013, will be reported in an oral presentation at the virtual 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) taking place from March ...

Spotlight on Scott Furlan Scott Furlan, pediatric oncologist Dr. Scott Furlan, a pediatric oncologist at Fred Hutchinson Cancer Research Center, believes he was drawn to bone marrow transplantation because of the sheer complexity of the challenge. “In pediatric transplant, each patient has a dizzying array of complex problems, each of which often has multiple solutions” Furlan said. To treat his young cancer patients, he has to sort through raft of possibilities and options, while helping parents navigate the frightful choices that lie ahead of them. “In pediatrics, we have the opportun...